Ketamine is a prescription anesthetic medication. Microdosing means taking very small amounts on a repeating schedule at home, mainly to lift low mood. Controlled research shows ketamine lifts low mood quickly at larger doses; whether the very small at-home amounts do is unsettled, and the best comparison suggests they work less well. Bladder damage, memory problems and dependence cluster at far heavier use; the safe ceiling is unmapped. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Blood Pressure | 110–120 / 70–80 mmHg at rest | Main cardiovascular effect; defines safe ceiling |
| Resting Heart Rate | 50–70 bpm | Tracks sympathetic activation and stimulant load |
| ALT and AST | ALT 10–26 U/L (women), 10–33 U/L (men); AST 10–26 U/L | Detects liver-cell injury from repeated exposure |
| GGT | <20 U/L (women), <25 U/L (men) | Earliest marker of biliary irritation |
| Serum Creatinine and eGFR | eGFR above 90 mL/min/1.73 m² | Upper tract involvement if injury progresses |
| Urinalysis (dipstick and microscopy) | No blood, no leukocytes, no protein | Earliest sign of bladder injury; reversible early |
| hs-CRP | Below 1.0 mg/L | Baseline inflammatory status |
| Fasting Glucose and HbA1c | Glucose 75–86 mg/dL; HbA1c 4.8–5.2% | Confirms no glucose drift with repeated use |
Cadence: Blood pressure before and 20 minutes after every dose for the first month, then monthly; urinary symptom review at 4 weeks, then every 3 months; blood panel at 3 months, then every 6 months; cognitive baseline annually, or sooner over 65.